Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial

Annals of Internal Medicine

Volumn 159, Issue 4, 2013, Pages 253-261

  Kremer, Joel ^a   Li, Zhan Guo ^b   Hall, Stephen ^c   Fleischmann, Roy ^d   Genovese, Mark ^e   Martin Mola, Emilio ^f   Isaacs, John D ^g   Gruben, David ^h   Wallenstein, Gene ^h   Krishnaswami, Sriram ^h   Zwillich, Samuel H ^h   Koncz, Tamas ^h   Riese, Richard ^h   Bradley, John ^h  

^a ALBANY MEDICAL COLLEGE   (United States)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c CABRINI INSTITUTE   (Australia)

^d METROPLEX CLINICAL RESEARCH CENTER   (United States)

^e STANFORD UNIVERSITY   (United States)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g FREEMAN HOSPITAL   (United Kingdom)

^h PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AURANOFIN; BAMINERCEPT; C REACTIVE PROTEIN; CANAKINUMAB; CERTOLIZUMAB PEGOL; CHLOROQUINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD SALT; GOLIMUMAB; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PLACEBO; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TOFACITINIB;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRONCHIECTASIS; BRONCHITIS; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC FOOT; DISEASE ACTIVITY SCORE; DISEASE CONTROL; DISEASE DURATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; HEALTH ASSESSMENT QUESTIONNAIRE; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPHIL COUNT; OPPORTUNISTIC INFECTION; PERITONITIS; PRIORITY JOURNAL; PULMONARY CRYPTOCOCCOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK; TREATMENT WITHDRAWAL; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JANUS KINASE 3; MALE; METHOTREXATE; MIDDLE AGED; PIPERIDINES; PYRIMIDINES; PYRROLES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84882266430     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-159-4-201308200-00006     Document Type: Article

References (24)

1. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, van Zeben D, Kerstens PJ, Gerards AH, et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis. 2007;66:1356-62. [PMID: 17293364]
2. Alarcón GS, Tracy IC, Blackburn WD Jr. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum. 1989;32:671-6. [PMID: 2735960]
3. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186:4234-43. [PMID: 21383241]
4. Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010;7:41. [PMID: 20701804]
5. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273-87. [PMID: 19290934]
6. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64:617-29. [PMID: 21952978]
7. Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012;64:970-81. [PMID: 22006202]
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24. [PMID: 3358796]
9. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-35. [PMID: 7779114]
10. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-45. [PMID: 7362664]
11. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8. [PMID: 7818570]
12. Askling J, Bongartz T. Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol. 2008;20:334-9. [PMID: 18388527]
13. Khraishi M. Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol Suppl. 2009;82:25-32. [PMID: 19509327]
14. Martin-Mola E, Balsa A. Infectious complications of biologic agents. Rheum Dis Clin North Am. 2009;35:183-99. [PMID: 19481004]
15. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56:2886-95. [PMID: 17729297]
16. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH; Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011;63:1150-8. [PMID: 21584942]
17. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al; ORAL Step investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451-60. [PMID: 23294500]
18. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al; ORAL Scan Investigators. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559-70. [PMID: 23348607]
19. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al; ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508-19. [PMID: 22873531]
20. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60: 1895-905. [PMID: 19565475]
21. World Health Organization. Tuberculosis country profiles. Accessed at www.who.int/tb/country/data/profiles/en/index.html on 1 November 2011.
22. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009;68:460-9. [PMID: 19286905]
23. Saiki O, Takao R, Naruse Y, Kuhara M, Imai S, Uda H. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. J Rheumatol. 2007;34:1997-2004. [PMID: 17787045]
24. McInnes IB, Kim HY, Lee SH, Mandel D, Song YW, Connell CA, et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis. 2013. [PMID: 23482473]